Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433000 | 0.86 | MAPT (0.60) | MAOBCYP2C9CYP2C19MAPTRAB9A | |
| SCHEMBL29960870 | 0.84 | NPC1 (0.61) | MAOBCYP2C9CYP2C19MAPTGAA | |
| SCHEMBL29083934 | 0.84 | NPC1 (0.61) | MAOBCYP2C9CYP2C19MAPTGAA | |
| SCHEMBL28362521 | 0.83 | KCNJ1 (0.64) | MAPTGAARAB9AARNPC1 | |
| SCHEMBL640338 | 0.82 | CYP2C9 (0.59) | MAOBCYP2C9CYP2C19MAPTSMN1; SMN2 | |
| SCHEMBL8622944 | 0.81 | CYP2C19 (0.57) | CYP2C9CYP2C19MAPTRAB9ANPC1 | |
| SCHEMBL4908272 | 0.81 | LMNA (0.59) | CYP2C9CYP2C19MAPTGAARAB9A | |
| SCHEMBL5372083 | 0.81 | CYP2C9 (0.65) | CYP2C9CYP2C19MAPTGAAHPGD | |
| SCHEMBL640295 | 0.80 | CYP11B1 (0.60) | MAOBCYP2C9CYP2C19MAPTGAA | |
| SCHEMBL17461847 | 0.79 | ALDH1A1 (0.52) | CYP2C9CYP2C19MAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1861393-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006092599-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | MAOB 1608/4885CYP2C9 215/4885CYP2C19 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.